What We Do
Alveo is leading the transformation of the consumer health tech market by developing a low-cost, easy- to-use, at-home diagnostic platform that has the potential to change the way infectious diseases are detected and managed. The company’s be.well™** testing system is designed to give individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic diagnostic platform could be adapted to detect a wide range of diseases that threaten public health. We believe affordable access to real-time, at-home results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks. With be.well™, we will Know Sooner, Act Faster™ and make better-informed decisions regarding personalized intervention options that benefit individuals and the entire population*..
Who We Are
We are scientists, innovators, data-geeks, and passionate entrepreneurs. We believe that every problem has a clear solution — when you apply the right knowledge and passion. We know that protecting the health of an interconnected global society has never been more crucial. We’re up to the challenge.
We are proud to be Alveo. Meet the team that is changing the world of diagnostics.
RON CHIARELLO, PhD
Ron earned a Bachelor of Science in Physics from the University of California at Santa Barbara and received his Doctorate in Physics from Northeastern University. Prior to his entrepreneurial career Ron spent more than a decade as a physicist and research program director at the University of Chicago and Stanford University. He has authored more than 50 scientific publications and patents, is an NSF Fellow, and has received awards for excellence from the Department of Energy, Argonne National Laboratory, the Chevron Clean Technology Open, and International SEMATECH.
MIKE AICHER, MBA
Mike holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University and is a certified Global Biotechnology Executive from the University of California, Berkeley. He has also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.
ROBIN STEELE, JD, LL M
Robin previously served eight years as Vice President of Legal Affairs for Elan Pharmaceuticals, a publicly-traded (NYSE) global pharmaceutical company headquartered in Dublin, Ireland.
Robin received a bachelor’s degree in biology from the University of Colorado, a J.D. degree from the University of California, Hastings College of the Law, and a LL.M. in Taxation from New York University School of Law.
BHARAT TEWARIE, MD, MBA
He gathered a compelling track record in structuring commercial organizations across settings, cultures, and geographies (USA and Europe) for profitable product performance and has been a catalyst for change and transformation in both global and local roles at Boehringer Ingelheim, Roche, Serono International, EMD Serono and Merck Serono.
After working for the last five years as the EVP & Chief Marketing Officer and member of the Executive Committee of UCB, he founded in 2020 the advisory firm Boston BioPharma Consultants and became a member of the Board of Advisors of Ahara Biosciences and Duluth Medical Technologies.
He is a thought leader on the topics of Patient Value, Product and Medical Device Launches, Patient Experience, Digital Technologies and specifically AI to address biopharma business challenges.
He joined Alveo Technologies in March 2020 as a member of the Board of Directors.
JOHNSON CHIANG, PhD
Johnson has led a number of molecular diagnostic product development projects from concept to commercialization at Applied MEMS, Applied Biosystems Inc., and Cepheid; designed and developed several successful microfluidics products; filed several patents; and published numerous biotechnology papers. He has extensive experience in instrument development as well as design control for 510k and PMA applications.
Prior to Alveo, Brenna held a variety of technical and leadership roles at Guidant Corporation/Abbott Vascular from 2004 to 2014, including: Group Lead of the design team for R&D implant projects; Principal/Staff Engineer focused on scaffold design and transfer to manufacturing for the first drug-eluting bioresorbable vascular scaffold to treat coronary artery disease; and Co-Chair of the Abbott Vascular Technology Exposition (2011-2012).
Brenna has successfully supported and led the development of multiple medical device products from early concept stage through design control, verification and validation, and regulatory submission. She holds 10+ patents and received the Abbott Vascular R&D Excellence Award in 2006, 2009, and 2010. Brenna earned her Bachelor of Science and Master of Science degrees from Stanford University in Mechanical Engineering.
Prior to his time with Alveo, Kyle worked at Entegris Jetalon as a New Product Development Engineer, serving as the team lead and taking multiple semiconductor sensor products from concept to market. Kyle received his Bachelor of Science degree from Arizona State University in Earth and Space Exploration.
Prior to Roche, Mitchell served as a Director for Kinetic Diagnostics, which utilizes genomic data in an effort to maximize athletic performance and at Laboratory Corporation of America (NASDAQ: LH) where he served in various finance and IT roles. Mitchell holds a Bachelor of Science in Business Administration and Entrepreneurship from Loyola Marymount University.
Prior to Siemens, Aman worked at Chrysler LLC where he was responsible for high-volume automation scale-up and manufacturing management across multiple new vehicle launches. Aman earned his Bachelor of Science and Master of Science degrees in Mechanical Engineering from Wayne State University and Oakland University respectively.
Kevin has successfully developed, implemented, and managed quality systems for a number of organizations, ranging from fledgling startups to established global corporations. He holds a bachelor’s degree in biological sciences from State University of New York at Buffalo and is an ASQ-certified Quality Auditor.
RIXUN FANG, PhD
He has worked through IVD product 510k and PMA submissions with FDA, initiated and led collaborative projects with many internationally well-known institutions, holds six patents, and has authored multiple publications.
ROBERT DI TULLIO
Robert was the Co-Chair of the AdvaMed Diagnostics Task Force from 2007 until 2013, the Diagnostics Industry Liaison to the Clinical Laboratory Improvement Advisory Committee (CLIAC) from 2011 until 2014 and is a long-time member of the Regulatory Affairs Professionals Society (RAPS). He was an advisory board member for the medical device graduate degree curriculum at the University of Southern California from 2004 until 2006. Robert received a Bachelor of Science in Biology from Saint Joseph’s University in Philadelphia.
Prior to Alveo, Shad worked at Entegris Jetalon as a Research Engineer, guiding the early stage development of multiple products. Shad has a bachelor’s degree in mathematics from the University of California, Davis.
Scientific Advisory Board Members
SUMITA PENNATHUR, PhD
Professor of Mechanical Engineering, UCSB, Director of Pennathur Laboratory for nanotechnology for bio sensing
PAUL BILLINGS, MD PhD
Chief Medical Officer, Life Technologies, Inc. acquired by Thermo Fisher (2014)
JAY G WOHLGEMUTH, MD
Chief Medical Officer, Quest Diagnostics
MARCIA EISENBERG, PhD
Chief Scientific Officer, LabCorp
CEO/Co–Founder of Zogenix (ZGNX)
CHARLES MOSHER, MBA
President and CEO of HemaStrat LLC
MYRON TONG, MD PhD
World–leading Hepatologist, practicing physician at UCLA Medical Center
GEORGE CHURCH, PhD
Professor at Harvard & MIT, Geneticist, molecular engineer, chemist
Managing Director of Virgo Investments Group
JOHN DEVINCENZO, MD
Professor at University of Tennessee, Medical Director Le Bonheur Children’s Hospital, pediatric RSV expert
KEVIN PLAXCO, PhD
Professor of Biomolecular Science and Mechanical Engineering, and the Associate Director of The Center for Bioengineering at UCSB
*The be.well™ system is currently under development to be used by individuals over the age of 18, and for individuals over the age of 18 to perform the test on individuals under 18 years of age.
** The be.well™ system is currently under development and has not received clearance, approval, or any other marketing authorization from the U.S. FDA.